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                                                           Abstract 
Screening methodologies have identified specific targets that could serve as potential 
therapeutic markers in cancer drug design, and the Retinoblastoma binding protein 6 (RBBP6) 
which is predominately expressed in lung and breast cancers is one critical protein identified. 
This study seeks to understand the 3D structure of RBBP6 domains, with emphasis on cancer. 
Three of these domains have been studied in this project, i.e. the Domain With No Name 
(DWNN), RING Finger, and the p53-binding domain. The ubiquitin-like structure of the 
DWNN has implicated this domain as a ubiquitin-like modifier of other proteins such as p53, 
whilst the RING Finger domain has intrinsic E3 Ligase activity like MDM2 the prototypical 
negative regulator of p53.  The DWNN and RING Finger domains have resolved solution NMR 
structures, whilst the p53-binding domain has none. Thus, the first initiative undertaken was to 
model the RBBP6 p53-binding domain using I-TASSER and eThread-Modeller web-severs. 
Our results demonstrated that this domain mainly constitutes of alpha-helices and loop 
structures. Structural quality validations of both I-TASSER and eThread-Modeller models 
were further assessed using Swiss-Model and ProSA (Protein structure analysis) web-servers. 
Analyses were focussed on specific statistical parameters (Anolea, DFire, QMEAN, ProCheck 
and the ProSA Z-score). Results from these analyses show that the first I-TASSER model is 
the best possible representation of the RBBP6 p53-binding domain depicting minimal 
deviation from native state. Furthermore, screening and docking studies were performed using 
Schrödinger-Maestro v10.7: Glide SP and drug-like molecules that would potentially serve as 
agonist or antagonist of RBBP6 were identified. 
Keywords: Retinoblastoma binding protein-6, MDM2, p53, DWNN, RING Finger, Virtual 
screening, Molecular modelling, Structural quality assessment, Docking, Agonist, Antagonist.   
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   1.1 Insight into the Retinoblastoma Binding Protein 6 (RBBP6) 
RBBP6 is a 250-kD multi-functional nuclear protein with several domains, found in all eukaryotes. It 
is implicated in a variety of cellular functions such as cell cycle regulation (Scott et al., 2003 and Kappo 
et al., 2012), mRNA metabolism (Witte et al., 1997 and Shi et al., 2009) , and development (Yoshitake 
et al., 2004 and Li et al., 2007). In humans, RBBP6 forms part of the pre-mRNA 3’-end processing 
complex (Vo et al., 2001) and is hypothesised to interact with tumour suppressors such as p53 and pRb 
(Witte et al., 1997). However, in mice PACT has been shown to exhibit a direct interaction with these 
tumour suppressors (Li et al., 2007).      
RBBP6 is composed of an N-terminal ubiquitin-like domain known as the DWNN (Domain With No 
Name) (Pugh et al., 2006), through which it facilitates ubiquitination. It also constitutes a cysteine-rich 
RING Finger-like domain which further promotes p53 ubiquitination by Hdm2 in an E4-like manner 
(Li et al.,2007). The RBBP6 RING Finger domain also interacts directly with the pro-proliferative 
transcription factor Y-box binding protein-1 (YB-1) (Eliseeva et al., 2011). In this instance RBBP6 
acts as a negative regulator of YB-1, as expression studies demonstrated that its over-activation in 
cultured mammalian cells leads to the suppression of YB-1 in a proteasome-dependent manner (Chibi 
et al., 2008). It remains unclear whether this illustrates an example of E4 (additional conjugation factor) 
or E3 (substrate specific ubiquitin-protein ligase)-like behaviour. Significantly, this over-activation 
triggers a down regulation of both the pro-apoptotic p53 and anti-apoptotic YB-1 which hints on the 
different roles of RBBP6 during tumorigenesis.    
The Retinoblastoma binding protein 6 gene is located on chromosome 16p12.2 in humans and encodes 
the RBBP6 isoforms. The RBBP6 gene is transcribed into two mRNA sequences of different sizes 
(1.1kb and 6.1kb), which then encodes four RBBP6 protein isoforms. Isoform 1 is encoded by the 
CHAPTER ONE: LITERATURE REVIEW  
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6.1kb transcript and upon alternative splicing; Isoform 2 and 4 emerges from the same transcript. 
Isoform 3 also known as the Domain With No Name (DWNN) as it is comprised of only this domain, 
is encoded by the 1.1kb transcript (Pugh et al., 2006).   
 1.2 Isoforms and 3-dimensional structures of RBBP6 domains  
The RBBP6 gene is composed of 18 exons within its coding region. Its isoforms: isoforms 1, 2, 3 and 
4 share a common N-terminal domain and are encoded by 18, 17, 3 and 11 exons respectively. These 
exons encode different domains within a single isoform. Consequently, the isoforms constitute 
different domain structures which implicate them in performing different cellular functions (Figure 
1.1). Thus isoforms 1 and 3 are significantly implicated in carcinogenesis whilst the functions of 
isoforms 2 and 4 have not been elucidated (Ntwasa, 2016).     
                                                                                                                                                                                       
                                                                                                           
                                                                                                               
                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                               
                                     
          
Figure 1.1: Illustrated domains encodes across different isoforms of RBBP6: The number of amino acid residues that 
constitutes each isoform is also represented.       
 
 
Number of 
Residues 
p53-binding domain  
Nuclear Localization signal  Rb-binding domain  
SR domain 
RING Finger domain  
Zinc Motif 
DWNN  
1792 
1758 
118 
952 
Isoform 1 
Isoform 2 
Isoform 4 
Isoform 3 
Key: 
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In this study, only isoform 1 was considered and three of its domains (DWNN, RING Finger, and p53-
binding domains) were analysed as potential drug targets. This is mainly because the zinc motif, serine 
rich domain (SR domain) as well as the nuclear localisation signal have no significant implication in 
carcinogenesis. However, the retinoblastoma binding domain (Rb-binding domain) targets the pro-
apoptotic retinoblastoma protein (pRb) which has critical cell-cycle regulating functions. This tumour 
suppressor protein (pRb) is mostly critical for retinoblastoma carcinomas in children, thus despite its’ 
tumour inhibitory effects the p53-binding domain (which binds the p53 tumour suppressor protein) 
was examined for potential drug-like inhibitors since the p53 protein is widely expressed in numerous 
cancers. This was done to provide a broader perspective of the potential drug-like inhibitors in 
carcinogenesis.                  
Currently, both the DWNN and RING Finger domains have resolved solution NMR (Nuclear magnetic 
resonance) structures (Figure 1.2&1.3), whilst the p53-binding domain has none. The N-terminal 
ubiquitin-like domain (DWNN) structure was firstly resolved using the Modeller software in the 
presence of a ubiquitin protein template. This application predicted an exact 3-dimensional structure 
like that resolved by solution NMR spectroscopy, despite the 22% sequence identity between them 
(Mather et al., 2005). The lysine residues on DWNN (mostly Lys48 and Lys63) are very critical in the 
ubiquitin template during substrate specific ubiquitin-protein ligase, they specifically facilitate the 
formation of peptide bonds between the ubiquitin moieties and various protein substrates (Figure 1.2). 
Thus, their presence in DWNN suggests that RBBP6 might be functioning with some form of ubiquitin-
like modification (Pugh et al., 2006).             
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Figure 1.2: Solution structure of the DWNN domain from human RBBP6: The structure was resolved using Nuclear 
magnetic resonance spectroscopy (NMR), and is composed of both alpha helices (blue) and beta sheets (green), as well as 
seven lysine residues (yellow). It was viewed using PyMOL and constitutes a PDB_ID: 1UBI, (Adapted from: Pugh et al., 
2006).  
The DWNN domain is expressed in higher vertebrates as a small independent protein (i.e. isoform 3), 
which further suggests that it may function as a novel ubiquitin-like modifier of other proteins (Pugh 
et al., 2006). Furthermore, isoform 3 has been shown to be down-regulated in most human cancers 
which hints its role in inducing cell cycle arrest or apoptosis (Mbita el al., 2012).  The DWWN has 
also been shown to form a crucial part of the multi-subunit protein complex, which mediates 
polyadenylation of mRNA precursors. This suggests that RBBP6 plays a role in regulation and covalent 
modification (addition of ubiquitin-like moieties) of pre-mRNA processing proteins (Pugh et al., 
2006).        
The RBBP6 RING Finger domain is made up of approximately 40 residues (including 8 conserved 
cysteines), and folds independently with the help of two zinc ions. These ions are coordinated by four 
pairs of cysteine residues in a “cross-braced” fashion. This means that one ion is co-ordinated by the 
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first and third Cys pairs while the other ion by the second and forth Cys pairs (Kappo et al., 2012). 
RING Fingers are therefore generally classified based on this zinc coordination pattern.    
There are several known RING Fingers such as C4C4, C3HHC3, C2H2C4 and C3HC4 which is the 
most common. The presence of the eight conserved cysteine residues suggests that RBBP6 contains a 
C4C4 RING Finger domain binding two zinc ions. Based on current literature this was confirmed using 
a directly detected 113Cd spectrum and the 1H – 113Cd HMQC spectroscopy (Kappo et al., 2012). In 
solution the RBBP6 RING Finger domain adopts a homodimeric structure, which forms a deep 
hydrophobic cleft at the interface of the two monomers (Kappo et al., 2012) (Figure 1.3).    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
Figure 1.3: Solution structure of the RING Finger-like domain from human RBBP6: The schematic depicts a 
secondary structure of the homodimer, with a hydrophobic interface consisting of a collection of hydrophobic residues 
(brown), including PHE314 which deeply projects into the opposite monomer. This interface is further stabilised by the 
triple-stranded β-sheets (green), C-terminal helices (pink) and asparagine (ASN312) which is positioned at the centre and 
forms a pair of reciprocal hydrogen bonds to its counterpart on the opposing monomer. The zinc ions are shown in yellow 
spheres, the structure was resolved using solution NMR and has been uploaded on the protein databank with PDB_ID: 
3ZTG, (Adapted from: Kappo et al., 2012).    
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Dimerization occurs within triple stranded β-sheets (green) forming a deep hydrophobic core interface, 
which is then stabilised by hydrophobic site chain interactions between the C-terminal helix and the 
N-terminal loop (including Loop L1 and L2 as shown in Figure 1.3) of the two monomers. Furthermore, 
positioned at the centre/core of the interface close to the 2-fold axis is asparagine (ASN312) which co-
ordinates a pair of reciprocal hydrogen bonds to its counterpart on the opposite monomer (Kappo et 
al., 2012). This co-ordination is like that observed in many U-boxes facilitated by ASN314 which 
occupies the same position in murine CHIP (Zhang et al., 2005).  
The structure also depicts a hydrogen bond co-ordination between SER278 and ASN312, which is 
supported by broadening of all resonances associated with SER278 (Kappo et al., 2012). Altogether, 
this network of polar interactions is likely to exhibit a strong stabilising effect on the homodimer and 
thus maintain the hydrophobic interface of the RING Finger domain. Site-directed mutagenic studies 
involving the change of ASN312 to aspartic acid (N312D) further abolished the homodimer completely 
(Kappo et al., 2012). Which hints on the significance of this residue (ASN312) in forming polar 
interactions that stabilises the homodimeric nature of this domain. 
Therefore, this hydrophobic interface is likely the catalytic site of the RING Finger domain, and thus 
gives RBBP6 its E3-ligase activity which then implicates it in p53 ubiquitination and other protein 
substrates such as pRb. Therefore, targeting this region with small molecular drug-like inhibitors might 
significantly re-activate p53 and pRb levels in cancer cells and thus prove useful in carcinogenesis and 
cancer therapy.      
1.3 Retinoblastoma Binding protein 6 as a potential drug target 
1.3.1 P53 protein as a tumour suppressor      
P53 is a widely-studied protein implicated in tumorigenesis. It is mutated or silenced in more than half 
of human cancers (Petitjean et al., 2007 and Danilova et al., 2010). The tumour suppressor protein 
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(p53) functions by modulating apoptosis and the cell cycle through regulating expression levels of its 
transcriptional targets (Ko et al., 2004; Ko et al., 2005 and Lee et al., 2008).  Thus, the absence of p53 
in cancer cells enable them to either evade cell cycle control, or fail to activate p53-dependent cell 
cycle arrest or apoptosis.  
Under normal conditions p53 responds to different forms of cellular stresses, such as hypoxia and DNA 
damage where it activates genes involved in growth arrest at G0 or G2/M phase of the cell cycle (Cheng 
et al., 2008). Furthermore, it induces the expression of pro-apoptotic proteins within the bcl-2 family, 
resulting in the induction of apoptosis in cells that cannot be repaired like those with damaged DNA. 
The p53 responses are therefore carried out by transcription factors of various p53 response genes (bax 
and p21) in normal cells.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
 1.3.2 The MDM2-p53 complex interaction           
The 3D structure of MDM2-p53 complex has been explored, and its stability relies on the role played 
by RBBP6 as a scaffold protein (Li et al., 2007). HDM2 (Human homologue of MDM2) is a 
phosphoprotein with 491 amino acids, and interacts with the α-helix NH2 terminal  transactivation 
domain of p53 through its NH2 terminal domain (Kussie et al., 1996). This interaction induces the 
blockage of p53 transcriptional activity and subsequent ubiquitination by MDM2 for proteasomal 
degradation (Moll et al., 2003). The biochemistry underlying MDM2 mediated p53 function inhibition 
have been explored using crystallography. This demonstrated that the N-terminal domain of MDM2 
forms a deep hydrophobic pocket where binding of the p53 transactivation domain occurs, implying 
that it is not involved in the interaction with the transcriptional machinery (Kussie et al., 1996).  
The interaction between MDM2 and p53 is restricted to a small hydrophobic cleft  (25-109 amino acids 
residue) and an amphipathic peptide containing 15 amino acid residues at the NH2 terminus of MDM2 
and p53 respectively (Kussie et al., 1996 and Moll et al., 2003).  
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Consequently, the minimal binding site of MDM2 on p53 was mapped within 18-26 residues, and site-
directed mutagenesis within this region demonstrated the significance of certain p53 residues such as 
LEU14, PHE19, LEU22, TRP23, and LEU26.  
Amongst these; PHE19, TRP23, and LEU26 are vital in binding the MDM2-hydrophobic cleft (Moll 
and Petrenko, 2003). Therefore, mutated p53 proteins are resistant to the MDM2-mediated proteasomal 
degradation, and similarly the mutation of MDM2 residues (GLY58, GLU68, VAL75, or CYS77) 
causes an inability to bind wildtype p53 (Moll et al., 2003). This hints on the significance of these 
residues from both proteins in the formation of stable MDM2-p53 complexes. 
The interacting domains depict a lock and key configuration of the MDM2-p53 complex, forming a 
dual-site interaction model (Figure 1.5). The p53 NH2-terminus constitutes amphipathic peptides, and 
therefore uses the alpha helical hydrophobic side which is formed by PHE19, TRP23, and LEU26 to 
bind deeply into the MDM2 hydrophobic pocket  (Kussie et al., 1996 and Patil et al., 2014) (Figure 
1.4).  
 
  
 
   
 
                                                                                                                                                                                                                                                  
Figure 1.4: The Crystal structure of MDM2-p53 interaction (pdb_id: 1ycq):  Shows the p53-transactivation domain 
(green) with 3 main residues (LEU26, TRP23 and PHE19) bound into a deep hydrophobic pocket (grey) of MDM2, which 
then promotes p53 inhibition and MDM2-mediated proteasomal degradation. The surface representation of grey concave 
regions in the MDM2 hydrophobic cleft illustrates its pocket-like nature of the domain (Adapted from: Patil et al., 2014).   
 
p53-transactivation domain  
   MDM2 hydrophobic cleft  
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The MDM2 cleft is formed by the 26-108 amino acid region and contains two structurally similar 
portions that folds into a deep groove of aromatic and 14 hydrophobic residues (Kussie et al., 1996, 
Moll and Petrenko, 2003). Hence, a tight binding mode is maintained between the p53-transactivation 
domain and MDM2.    
 
 
 
 
 
Figure 1.5: Domain structures of MDM2 and p53 illustrating positive effect binding: The p53 BOX-I domain binds 
the N-terminal hydrophobic pocket of MDM2, whilst there is also binding of the MDM2 central acidic domain to the p53 
BOX-V domain. This forms the “dual-site” model of p53 MDM2-mediated ubiquitination (Goh et al., 2014).  
 
2.3.3 Scaffold activity of RBBP6   
The E3 ubiquitin ligase activity of p53-associated cellular protein-testes derived (PACT also known as 
RBBP6) implicates it in acting as a scaffold protein promoting the assembly of HDM2 (Human double 
minute 2)-p53 complexes, resulting in an increased HDM2-mediated ubiquination and proteasomal 
degradation of p53 (Li et al., 2007). This suggests that RBBP6 might act as a negative regulator of p53, 
inducing cell growth or cell proliferation when upregulated and promoting a p53-dependent cell cycle 
arrest or apoptosis when down regulated. Thus, RBBP6 indirectly affects the cell cycle through 
interacting with HDM2 and together regulate cellular levels of p53 (Li et al., 2007).  
Therefore, the involvement of RBBP6 in facilitating HDM2-p53 assemble is crucial in hypothesizing 
its role as a possible anti-cancer drug target. Designing of small drug-like molecules that can disrupt 
the RBBP6-HDM2 interaction (scaffolding activity), could serve as an alternative way of inhibiting 
the formation of MDM2-p53 complexes to reactivate p53 levels in cancer cells.   
Hydrophobic pocket Acidic domain ZF RING 
BOX-I BOX-V 
MDM2 
p53 
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1.4 Rational drug design 
Drug discovery has increased quite significantly based on the availability of  X-ray Crystallographic 
or NMR (Nuclear magnetic resonance) protein structures, development of structure guided computer-
aided methodologies, as well as docking tools (Mandal et al., 2009). Despite this increase, developing 
lead molecules (small molecules of desired properties) and effective drug targets remains challenging 
even for known targets. The protein data bank (PDB) is currently estimated to hold over 100,000 3D 
structures, but this number is still relatively insignificant as some of these biomolecules have multiple 
structures binding to different molecules. Most important target 3D structures are still unknown based 
on the limitations on the throughput and applicability of protein size presented by both NMR and X-
ray crystallography. Therefore, this delays the drug-discovery process and have prompted a quest for 
complementary analytical tools that can detect local conformation changes with high sensitivity and 
experimental throughput (Yu et al., 2013).     
Recent advances in elucidating high-order structures (HOS) is based on the underlying principles of 
HDX-MS, which stands for Hydrogen-deuterium exchange mass spectrometry. This technique seeks 
to counter act the limitations posed by conventional methods, by increasing its sensitivity upon 
flexibility and molecular dynamics analysis of protein structures (Wales et al., 2006; Fang et al., 2010 
and Hebling et al., 2010). HDX-MS is also capable of monitoring domain interaction, localised protein 
breathing and folding or unfolding in solution. The principle behind HDX-MS is mainly based on a 
chemical phenomenon in which the amide hydrogen atoms (NH) on the protein backbone, exchange 
with deuterium atoms on the surrounding solvent or gas (Yu et al., 2013). The coupled mass 
spectrometer then detects where the exchange took place in the molecule (i.e. at the protein, peptide or 
single amino acid level) (Engen et al., 2009).             
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In addition to these advances, newly improved approaches of rational drug design are also necessary 
to overcome problems in structure guided computer aided-drug design. 
The rational drug design methodology generally encompasses two critical approaches: 
 Development of small drug-like molecules for targeting cellular proteins or enzymes whose 
functional  roles in cellular processes and 3D structural information are well-defined (Mandal et 
al., 2009). 
 Development of small drug-like molecules with desired chemical properties for targets, whose 
cellular functions and 3D structural information may or may not be known. Advanced 
computational tools can be  utilised to retrieve knowledge of unknown targets by performing global 
gene expression data analysis of drug treated and untreated samples (Mandal et al., 2009). 
The final process in rational drug design focuses on the balance between hydrophilicity and 
pharmacokinetics (ADME) as well as the electrophilicity, nucleophilicity and biodegradation (radical 
attack). During this process toxicity is also thoroughly examined due to the biotransformation at 
different phases of metabolism. This examination is done using QSAR (Quantitative structure-activity 
relationship) and QSPR (Quantitative structure property relationship). Gene expression profiling and 
bioinformatics analysis are further applied to gain insight of the gene expression patterns immediately 
after the initial evaluation and identification of lead molecules (Mandal et al., 2009). 
This insight can then be utilised to improve drug potency which measures Eradication of disease, 
elimination or minimization of toxic side effects, reduction of undesirable biotransformation, 
improvement in distribution (bioavailability), overcoming of drug resistance, and improvement of the 
immune response (Mandal et al., 2009).  
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1.4.1 Structure guided computer-aided drug design      
Structure guided methodologies remains a major part of drug discovery and development for known 
3D structures of potential drug binding site. In structure guided-drug design various state-of-the-art 
tools (X-ray Crystallography, Nuclear magnetic resonance (NMR) and Hydrogen Deuterium Exchange 
– Mass spectrometry (HDX-MS)) are used to determine the 3D structures of targets complexed with 
their ligands or drug molecules, thus providing hints on binding site location. This serves as the first 
step towards structure guided drug design for known targets in lead discovery. After the ligand bound 
3D structure is known, virtual screening of a large collection of chemical compounds such as those of 
the ZINC database can be performed (Irwin et al., 2005). This screening approach enables 
identification of new potential drugs by performing docking experiments of these chemical 
compounds.  
 The newly discovered compounds (lead compounds) are further tested for biological potency to 
improve their binding affinity and specificity, then statistical analyses and relationships (QSAR, 
QSPR) can be performed to ascertain the potential molecules for lead drug discovery. When working 
with an FDA approved database, lead molecules can be used to determine their current 
pharmacokinetics behaviour (ADME) and reactivity (Mandal et al., 2009). To prevent undesirable 
metabolic fate, further modifications of the lead molecule should be performed through examination 
of molecular reactivity. This is done by considering the following properties: electrophilicity, 
nucleophilicity, or radical attacks.  
Furthermore, the optimised pre-clinical drug candidates should be examined to ensure that they possess 
desirable drug-like properties (pharmacokinetics). These properties include, Log P, molar refractivity, 
number of acidic & basic like molecules, and molecular weights (Mandal et al., 2009), and they were 
formulated by Lipinski et al (Lipinski et al., 1997) and later developed by Ghose et al (Ghose et al., 
1999). Computational power is then used to assess the toxicity of the optimised drug-candidates and 
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their respective metabolites. However, this is thoroughly further investigated and confirmed using in 
vitro assays.     
Small molecules must possess specific chemical properties (mentioned above), and exert the desired 
pharmacological effect to be classified as a drug-like molecule. Thus, the principle underlying rational 
drug design encompasses the detailed evaluation of all such properties (Mandal et al., 2009). 
 1.5 Protein Modelling     
Generally, molecular modelling accommodates all kinds of theoretical methods and computational 
techniques used to model and mimic the behaviour of molecules. It is a widely-used technique to study 
molecular systems ranging from small chemical systems to large bio-molecular systems. 
One of the ultimate goals in protein modelling is the prediction of protein 3D structures from their 
amino acid sequences. This prediction, however, remains intricately complex as multiple different 
amino acid sequences have the potential to form similar functional protein structures. Protein structural 
alignment is therefore important in protein modelling and uses computational graphics to super-
position two or more structures. This can reveal conserved  features in two related proteins or 
differences in the conformational changes during allosteric transition or upon complexation (Tsai, 
2002). 
There are two ways in which structures can be superimposed. First, by displaying structures using 
interactive graphics to provide the facility to rotate and translate one with respect to the other. This 
involves superimposing the two structures by “simple visualisation”. The second method is numerical 
and involves selecting corresponding sets of atoms from two structures, a program can then calculate 
the best ‘‘least-square fit’’ of one set of atoms to another. These two methods are equally important; 
eye fitting or visualisation permits rapid experimentation to assess the goodness of fit in different 
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portions of the molecules, while numerical fitting permits quantitative comparisons of the relative 
goodness of fit of different structures and sub-structures (Tsai, 2002).  
When superposing two protein structures such that the corresponding atoms in the well-fitting regions 
are optimally matched, two aspects needs to be considered. They include; choosing the corresponding 
sets of atoms from the two structures, and finding the best match of these corresponding atoms (Tsai, 
2002).  
However, the principle underlying homology modelling comprises major limitations when modelling 
proteins or domains that has no conserved sequence or structural regions to currently resolved 
structures (in PDB). Thus, fragment assembly modelling has been one major approach utilised to 
counter-act such limitations. This technique, works by using approximately 10 different structural 
templates on which all have some degree of homology to the query sequence. These templates are then 
fragmented based on their aligned regions, and then later ligated by Replica-exchange monte Carlo 
simulations, creating structural decoys. The published softwares using such simulations include I-
TASSER, 3D-Jigsaw etc. 
Recent advances on this field also led to the development of template-free modelling tools such as 
QUARK (Xu et al., 2012). This works by incorporating ab intio algorithms with Replica-exchange 
monte Carlo simulations and both work to construct protein’s 3D models from only the amino acid 
sequence. These techniques attempt to mimic in vivo molecular dynamics and incorporates protein 
folding mechanics to achieve high quality models with supreme accuracy (Xu et al., 2012). Thus, they 
are currently major drivers of protein modelling.                
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2.1 Main aim 
To find drugs that would target the retinoblastoma binding protein 6 (RBBP6) domains for cancer 
therapy  
2.2 Objectives 
1. Modelling the RBBP6 p53-binding domain 
 Protein domain Modelling using I-TASSER and eThread-Modeller web-applications  
 Structural Quality Assessment using Swiss-Model and ProSA web-applications 
2. Binding site prediction of the DWNN, RING Finger, and p53-binding domains 
3. Screening of chemical compounds and Molecular docking using Schrödinger-Maestro v10.7: 
Glide SP (Standard precision)  
 The virtual screening was done to determine potential drug-like compounds that could serve 
as agonist and antagonist of RBBP6    
 Molecular docking was performed to 3D structures having the lowest possible Gibbs free 
energy (∆G) 
 The Zinc drug database (Zdd) containing 2924 structures was utilised in all docking studies 
     2.3 Hypothesis 
Drugs can bind the retinoblastoma binding protein 6 (RBBP6) domains (DWNN, RING Finger, and 
p53-binding domains) with high affinity. 
 
 
CHAPTER TWO: AIMS AND OBJECTIVES     
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3.1 Materials 
3.1.1 Computational tools  
 
Table 3.1: Software tools used during molecular modelling and docking studies.   
 
  
Software Name Web-site Publisher 
I-TASSER (Iterative-
Threading ASSEmbly 
Refinement)  
http://zhanglab.ccmb.med.umich.edu/I-
TASSER/ 
 
Yang Zhang Lab, 
University of Michigan 
eThread-Modeller  http://brylinski.cct.lsu.edu/content/webservices 
 
Computational Systems 
Biology Group, 
Louisiana State 
University 
Swiss-Model http://swissmodel.expasy.org/workspace/ 
 
Swiss-Institute of 
Bioinformatics, 
Biozentrum University 
of Basel 
ProSA (Protein 
Structure Assessment) 
https://prosa.services.came.sbg.ac.at/prosa.php 
 
Markus Wiederstein, 
Centre of Applied 
Molecular Engineering, 
University of Salzburg 
FTSite: Binding site 
prediction server  
http://ftsite.bu.edu/ 
 
Structural 
Bioinformatics Lab, 
Boston University 
Zinc Drug Database 
(Zdd) 
http://zinc.docking.org/browse/subsets/special 
 
Shoichet Lab, 
University of California, 
San Francisco  
Schrödinger-Maestro 
v10.7 
https://www.schrodinger.com/ (Licence Needed) Schrödinger, New York 
City, California  
UniprotKB http://www.uniprot.org/uniprot/Q7Z6E9  Uniprot Consortium 
  CHAPTER THREE: MATERIALS & METHODS  
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3.2 Methods 
3.2.1 Modelling the RBBP6 p53-binding domain 
 
The RBBP6 p53-binding domain (p53BD) has not been modelled or neither does it have an NMR or 
X-ray crystallographic structure. Therefore, in this study the p53BD was modelled, using I-TASSER 
(Iterative-Threading ASSEmbly Refinement) and eThread-Modeller web-servers.  
I-TASSER constitutes an inherent structure fragment assembly approach, which consistently drives the 
threading alignments closer to native state (Zhang, 2008). This application identifies structural 
templates from the PDB library using a multiple threading approach called LOMETS. These structural 
templates are excised into continuous fragments based on the threading alignments, and full-length 
atomic models are constructed by replica-exchange Monte Carlo simulations (iterative template 
fragment assembly simulations) with the threading unaligned regions built by ab initio modelling (Roy 
et al., 2010). Using spatial restraints from both LOMETS templates and PDB structures by TM-align, 
a further fragment assembly calculation is performed starting from the SPICKER cluster centroids 
(Figure 3.1). This is done to remove steric clashes and refine the global topology of the cluster 
centroids. The computed decoys of this second simulation are clustered in which the lowest energy 
structures are selected (Roy et al., 2010). Ultimately, using the selected I-TASSER decoys REMO 
builds the atomic details of the final full-atomic models through hydrogen-bonding network 
optimisation. Lastly, functional insights of the target are derived by threading the 3D models through 
a protein function database (BioLiP) (Yang et al., 2015) (Figure 3.1).  
Furthermore, eThread-Modeller is a template-based protein structure prediction tool that uses a 
machine learning approach to Meta-threading and modelling of protein tertiary structures (Brylinski et 
al., 2012). Templates are also selected from the PDB library using Meta-threading that combines ten 
individual threading or fold recognition algorithms.    
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Figure 3.1: I-TASSER protocol for protein structure and function prediction: The server firstly retrieves templates 
from PDB using LOMETS, and further performs multiple iterative-structure fragment assembly simulations to determine 
the final models. Functional insights are finally derived by threading the final 3D models through a protein function database 
(BioLiP) (Adapted from: Zhang, 2008).  
The RBBP6 p53BD constitutes 111 amino acids sequence in length and was retrieved from the 
UniprotKB database (Unique entry identifier: Q7Z6E9), with domain positions ranging from 1433-
1544 amino acids. This region was taken up by both servers as inputs. Default settings were used in 
both I-TASSER and eThread-Modeller such that no algorithmic scripts were written to assist the 
servers. The generated outputs (predicted p53BD models) were then assessed for quality using quality 
assessment web-servers such as Swiss-Model and ProSA (Protein Structure Assessment). These 
servers considered a wide spectrum of statistical parameters, ranging from both local to global accuracy 
predictions to precisely evaluate the models’ native state. Thus, the most plausible RBBP6 p53BD 
model was selected.      
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3.2.2 Structural Quality Assessment using I-TASSER, eThread-Modeller, Swiss-Model 
and ProSA web-servers 
 
The Iterative-Threading ASSEmbly Refinement and eThread-Modeller applications used various 
statistics to rank obtained models. These statistical parameters ranged from the Confidence score (c-
score), Root Mean Square Deviation of atomic positions (RMSD), Template Modelling score (TM 
score), and the Global Distance Test-total score (GDT_TS). The RMSD is the measure of the average 
distance between atoms (backbone atoms) of two superimposed protein structures, and is represented 
by the equation below: 
    
Where d represents the square of the distance between two given atoms, and n represents the total 
number of atoms present. In instances where the two superimposed structures are identical, the RMSD 
value would be 0Ǻ. Therefore, the larger the RMSD the more dissimilar the structures are. TM-score 
measures the degree of similarity between two proteins possessing different tertiary structures. The 
TM-score measures this similarity using a score ranging from (0 – 1), where 1 indicates a perfect match. 
The GDT_TS is the measure of similarity between two proteins with identical amino acid sequences 
but different tertiary structures. This is a preferred parameter compared to RMSD, since it’s sensitive 
to outliers generated by poor modelling of individual loops in a reasonably accurate structure. 
Both the Swiss-Model and ProSA (Protein Structure Assessment) web-servers stipulated further 
statistical predictions on the generated models. These predictions were based on five parameters 
namely; ANOLEA, Dfire, QMEAN, ProCheck, and the ProSA z-score. The ANOLEA (Atomic Non-
Local Environment Assessment) is the atomic empirical mean force potential, and is used to assess 
    Equation 3.1 
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packing quality of the models (Melo et al., 1998). The program performs energy calculations on a 
protein chain, evaluating “Non-Local Environment” (NLE) of each heavy atom in the molecule.  
The Dfire is an all atom statistical potential based on a distance-scaled finite ideal-gas reference state. 
This parameter is used to assess non-bonded atomic interactions in a protein model. A pseudo energy 
for the entire model reflecting its quality was provided, a lower energy indicates that the model is closer 
to native state (Zhou et al., 2002). The QMEAN is a composite scoring function for both the estimation 
of global quality of the entire model as well as for local per-residue analysis of different regions within 
the models. For this study, the local per-residue analysis was performed. The ProCheck focuses on the 
stereochemistry assessment of the models, and it assesses the geometry of residues in each protein 
structure, as compared with stereochemical parameters derived from well-refined, high-resolution 
structures. ProSA z-score indicates overall model quality and its value is displayed in a plot that 
contains the z-scores of all experimentally determined protein chains in the current PDB (Wiederstein 
et al., 2007). Therefore, it was used in this study to check whether the z-score of the input structure 
(modelled RBBP6 p53-binding domain) is within the range of scores typically found for native proteins 
of similar size.  
3.2.3 Binding site prediction  
The modelled RBBP6 p53-binding domain, DWNN, and the RING Finger domain structures were then 
subjected to FTSite Web-server. This was to identify potential binding pockets in all three domains. 
Binding site prediction is an important technique and constitutes a variety of applications such as 
structure-based function prediction, protein functional relationship elucidation, protein engineering and 
drug design. In this study, the technique was applied in the context of small-molecular drug design. 
The FTSite web-server was used as a binding site identification tool and is based on NMR (Hajduk et 
al., 2005) and X-ray crystallographic (Mattos et al., 1996) experimental evidence, that ligand binding 
sites possess a tendency to bind small organic molecules of various shapes, size and polarity. FTSite 
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constitutes a solvent mapping algorithm (Brenke et al., 2009) which is an exact computational analogue 
of NMR and X-ray Crystallography. 
FTSite identifies regions that have the highest number of non-bonded interactions with overlapping 
low energy clusters of several small molecular probes (Ngan et al., 2012). This is achieved by using 
computational mapping that works by placing 1 of 16 different small molecular probes on a dense grid 
around a given protein, and finds favourable positions using empirical free energy functions. Individual 
probes are then clustered and ranked based on average free energy (Ngan et al., 2012). Following this, 
consensus clusters are identified as binding sites where different probe clusters overlap. The consensus 
clusters are then ranked based on the total number of non-bonded interactions between the protein and 
all probes in that cluster (Ngan et al., 2012). Consensus clusters are ranked from the highest number 
of contacts to the lowest. The amino acid residues in contact with the probes of the newly defined 
cluster constitute the top ranked predicted ligand binding site. Thus, clusters with fewer contacts are 
defined as lower ranked predictions (Ngan et al., 2012). The use of multiple probes sets FTSite apart 
from other energy-based methods, and the use of NMR and X-ray Crystallographic evidence improves 
its robustness on conformational chances. Thus, it is currently one of the leading protein binding site 
prediction severs with supreme accuracy on prediction irrespective of evolution or statistical data. 
Results obtained from this application were then used as basis of Grid generation prior the ligand 
docking process.  
3.2.4 Screening of chemical compounds and Molecular docking 
 
The three RBBP6 domains (DWNN, RING Finger, and p53-binding domain) were used as templates 
on the Schrödinger-Maestro v10.7: Glide SP (Standard Precision) application to screen the Zinc drug 
database (Zdd) for chemical compounds that can target characterised binding sites. The Zdd constitutes 
commercially FDA approved drugs, available worldwide as pure compounds. In this study, the entire 
Zdd database which had 2924 structures was screened. The use of Glide enabled both virtual screening 
                                                                                                                                                        
 
22 Charmy Starnod Twala, Master of Science in biochemistry and bioinformatics  
and molecular docking studies to be simultaneously performed. This application took-in respective 
domain structures and the Zdd as inputs, and generated a collection of chemical compounds docked 
into specified pockets with different binding affinities.    
The Schrödinger’s Receptor-based ligand docking protocol employs a multi-step procedure, which in 
this study involved the preparation and manipulation of protein domains as well as ligands prior to 
ligand-docking. These steps were sequentially performed as follows: Protein domain preparation, 
Ligand Preparation, Grid generation and Receptor-based ligand docking. 
3.2.4.1 Protein domain preparation  
 
The Protein Databank (PDB) structures are not suitable for immediate use in molecular modelling 
calculations, as they usually consist of only heavy atoms. They may also include: core crystallised 
ligand, water molecules, metal ions and co-factors. Additionally, some structures are multi-meric and 
need to be reduced to a single unit, and because of the limited resolution of X-ray experiments it can 
be difficult to distinguish between the carbonyl oxygen and the secondary amine nitrogen of the amides 
in crystal structures thus the placement of the groups must be checked. PDB structures may also be 
missing atoms or connectivity information which must be assigned along with bond-orders and formal 
charges. 
Therefore, in this study the Schrödinger-Maestro v10.7 protein preparation wizard was used. This took 
all the three RBBP6 domains from their raw state (having missing atoms or incorrect bond-order 
assignments, incorrect charge states and orientation of various groups) and brought them to a suitable 
state of being utilised by Glide. The wizard contains a Graphical User Interphase (GUI) with a 
systematic functional procedure that can be briefly described as follows;   
 The “import and process” tab imports structures and perform basic tasks fixing the structure. 
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 The “Review and Modify” enabled the deletion of unwanted chains and waters and fix or delete 
head groups. 
 The “Refine” tab allowed for the optimising orientations of Hydrogen bonded groups and minimise 
the structure.        
These functionalities provided a very convenient way in the successful preparation of all three RBBP6 
domains.  
3.2.4.2 Ligand Preparation 
 
The Zinc drug database was downloaded (http://zinc.docking.org/browse/subsets/special) in SMILE 
and SDF formats which contained 2D structures of chemical compounds. This configuration state is 
not suitable when performing molecular docking calculations, or to simulate using computational 
docking algorithms. Proteins exist in 3-dimensional space, thus drugs that would successfully target 
them should also exhibit such configuration. Therefore, the Schrödinger-Maestro v10 .7 ligand 
preparation wizard was used to convert 2924 2D structures into lowest energy possible 4909 3D 
structures in a maestro format. This program allows for an expansion of each input structure by 
generating variations on the ionisation state, tautomer’s, stereochemistry, and ring conformations.   
The possible ionisation states of the ligands were generated at a target pH range; 7.0 +/- 2, using Epik 
which is a built-in application within Glide that predicts both the ionisation states and their associated 
penalties. Epik also predicted different tautomeric forms and calculated energetic penalties for every 
ligand state it predicts. In Glide, the Epik state penalty is also used to differentiate active from inactive 
compounds during docking, in fact the use of Epik is known to improve virtual screening enrichment.       
3.2.4.3 Grid Generation  
 
The outer scoring grids were generated with different dimensions ranging from 20x20x20Ǻ to 
50x50x50Ǻ in x, y, z - axis respectively. Generally, it is important to make the outer grid consistent 
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with the shape of the protein’s active site, thus this was done to only cover-up the active site volume 
in each of the three RBBP6 domains (DWNN, RING Finger and p53-binding domain) plus the MDM2 
p53-binding hydrophobic cleft. The results obtained from FTSite (Binding site characterisation) were 
used as a premise to accurately map-out critical residues facilitating the binding co-ordination in all 
the above-mentioned domains.   
Furthermore, a ligand centre box (inner grid) was generated. This defines the acceptable ligand centre 
positions during the side point search, and gives a true measure of the effective search space size. The 
ligand centre box is useful for ligands to find usual or asymmetric binding modes in the active site or 
to confine their midpoints into a smaller box to save calculation time. The “centroid of selected 
residues” option, which specifies the residues that best define the active site was also used, and the 
inner grid was then centred on the centroid of these selected residues.      
3.2.4.4 Receptor-based Ligand docking 
 
The final docking algorithm utilised in this study is the Glide SP-algorithm, better known as the 
standard precision. The nature of docking simulations employed by this algorithm are the same to that 
of the High Throughput Virtual Screening (HTVS). Thus, both methods use the same scoring functions, 
except that HTVS reduces the number of intermediate conformations throughout the docking funnel, 
the thoroughness of the final torsional refinement and sampling. During the docking process, the 
domain-structures were kept rigid (not even the hydroxyl and thiol groups could rotate), and flexibility 
was induced to all docking ligands. This was achieved through the ligand preparation wizard, which 
had generated a collection of multiple possess of the ligand database (Zdd). The entire work was done 
using a Core i7 with 4 cores, 8 processors, 8GB of RAM, and only six docking jobs were performed.    
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Figure 3.2: Flow diagram of the adopted methodology: Representing the adopted methodology underlying 
structure guided computer-aided drug design. The green region indicates a broader concept of the method 
performed, whilst the blue area specifies the processes performed in each method. Applications and web-servers 
used in each process are highlighted in red on the bottom light-grey boxes.        
 
 
 
 
Summary: Methodology underlying structure guided computer-aided drug design 
Template identification 
Binding site prediction 
Lead discovery 
Structure based-
Virtual screening  
Molecular docking Protein domain modelling  
Binding site / 
Pocket detection  
FT Site-Webserver: Ligand 
Binding Site Prediction 
 
 Uses a solvent mapping 
algorithm that considers 
NMR and X-ray 
Crystallographic evidence. 
 
 Identifies highest number 
of non-bonded interaction 
regions with overlapping 
low energy clusters of 
small molecular probes. 
  
 
 
     
 
I-TASSER (Iterative-Threading 
ASSEmbly Refinement server)  
 
 Uses LOMETS to identify 
templates from PDB. 
 
 Works by constructing full-
length atomic models by 
iterative template fragment 
assembly simulations.   
 
 eThread-Modeller was used 
for comparison.   
 
 
 
Maestro 10.7: Glide SP (Standard 
Precision)  
• Protein Preparation 
• Ligand Preparation 
• Grid Generation  
• Receptor-Ligand docking         
Using the Zinc drug database 
(ZDD) which is FDA Approved   
 
Database size = 2924 to 4909 
lowest energy possible 3D 
compounds 
 
• Used a Core i7, 4 cores, 8 
processors, 8GB RAM 
• 6 docking jobs were performed 
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4.1 Six plausible RBBP6 p53-binding domain models  
Since the RBBP6 p53-binding domain (p53BD) has not been modelled nor crystallised, this section 
seeks to close such gaps. Six top models (i.e. Model-A, Model-B, Model-C, Model-D, Model-E, and 
Model-F) demonstrating a tertiary structural fold of the p53BD sequence were chosen and are reported. 
These models were predicted using I-TASSER (Model-A, Model-B and Model-C) and for comparison, 
eThread-Modeller (Model-D, Model-E, and Model-F) was also utilised.  
Both I-TASSER and eThread-Modeller used various statistical parameters composed of both local and 
global accuracy predictions to rank the predicted models. I-TASSER used the c-score, TM-Score, and 
the RMSD for global accuracy, whilst the built-in Residue Quality program (ResQ) was utilised for 
local accuracy predictions (Figure 4.1). Similarly, eThread-Modeller calculated the global distance test 
total scores (GDT_TS) for each generated model (Figure 4.2). Analyses based on these parameters 
show that Model-A and Model-D, generated from both severs, are the best models which may resemble 
the native state. Other web-severs; Swiss-Model and ProSA were used to validate the structural quality 
of these models and to select one model that best represent the native state of the RBBP6 p53BD.          
4.1.1 Modelling by Iterative-Threading ASSEmbly Refinement (I-TASSER)   
 
I-TASSER simulations generated a large ensemble of structural conformations, called decoys for the 
RBBP6 p53BD query sequence. When selecting the final models, I-TASSER used the SPICKER 
program to cluster all decoys based on their pair-wise structure similarity. Here, the top 3 of 5 models 
representing the RBBP6 p53BD produced by LOMETS are reported (Figure 4.1). The confidence of 
each model is quantitatively measured by the c-score that is calculated based on the significance of 
threading template alignments and the convergence parameters of the structure assembly simulations. 
      CHAPTER FOUR: RESULTS  
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The acceptable c-score ranges from -5 to 2, where a c-score of a higher value signifies a model with 
higher confidence and vice-versa. The TM-align and RMSD scores are estimated based on the c-score 
and protein length. Thus, of the three models, Model-A with the highest c-score is the most probable 
model representing the RBBP6 p53BD.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Estimated TM-score = 0.42±0.14,  
 Estimated RMSD = 9.8±4.6Å  
Figure 4.1: Three possible RBBP6 p53-binding domain models resolved by I-TASSER: [A–C] Represent the predicted 
tertiary structures of Model-A, Model-B and Model-C along with their confidence scores (C-scores). The corresponding 
graphs [1–3] depict local accuracy predictions of all three models resolved by the ResQ (Residue Quality and B-factor) 
algorithm, black and red dots below the graphs represent coils and helices respectively which corresponds to the secondary 
structure prediction of the query sequence and has been resolved using the built-in Psipred algorithm within I-TASSER. 
A 
C –Score = - 2.57 
1 
C –Score = - 3.93 
B 
C –Score = - 4.66 
C 
2 
3 
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Global accuracy prediction of the models was also assessed using both the TM-align and RMSD scores, as shown in bullet 
form below the models.         
Since the top 5 models are ranked by the decoy cluster size, it is possible that the lower-ranked models 
have a higher c-score in rare cases. High c-scores of lower ranked models can result in better quality 
compared to highly ranked models with lower c-scores. If I-TASSER simulations converge (reaches a 
perfect match), it is possible to have less than 5 clusters or models generated. This would mean that 
the query sequence precisely aligned with one template from the PDB library, thus indicating good 
quality of the generated model because of the converged simulations. 
The local accuracy in figure 4 (1-3) reflects the distance of deviation (in Angstrom) between residue 
positions of the models and the native state (Figure 4.1(1-3)). Since the native structure is unknown, 
the distance errors in the plots above are estimated by the ResQ (Estimation of Residue Quality and B-
factor) algorithm using support vector regression that makes use of the coverage of threading 
alignment, divergence of I-TASSER simulation decoys, sequence-based secondary structure as well as 
solvent accessibility predictions. 
All these models form a mixture of helices and loops structure. However, Model-A seems to have very 
little deviation (approximately 1-1.5Å) from native state in terms of its local accuracy prediction 
(Figure 4.1 (1)). Therefore, these local accuracy prediction scores imply that Model-A is the best 
possible representation of the native state compared to Model-B and Model-C, since there is greater 
local accuracy deviation (above 3.5Å) in graph 2 and 3 respectively. The Global accuracy of the models 
has also been predicted by I-TASSER using usual statistical parameters (i.e. c-score, TM-score and 
RMSD score). Reported here is the quality prediction (TM and RMSD) of Model-A, since the 
correlation between c-score and TM-score is weaker for lower rank models. However, the c-score 
values of the models decrease from Model-A to Model-C as shown, suggesting that the RBBP6 p53BD 
is more likely to fold in a pattern resembling that of Model-A. 
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4.1.2 Modelling by eThread-Modeller   
 
The eThread-Modeller web-application also employs a Meta-threading approach that combines ten 
individual threading or fold recognition algorithms. Here, eThread-Modeller was used as a comparison 
tool to observe the relationship between its predicted models and those generated by I-TASSER. 
Interestingly, a similar folding pattern of the models predicted by these two applications was observed 
(i.e. the helix-loop pattern nature) (Figure 4.2). Since these web-applications consider different sets of 
parameters and use unique computational calculations for structure prediction, these findings increased 
confidence in the models and importantly the structural geometry of the RBBP6 p53BD. Notably, the 
GDT_ TS below decreases from Model-D to Model-F implicating that the Global accuracy of Model-
D surpasses that of Model-E and Model-F and thus represents the best model of the RBBP6 p53BD 
generated by eThread-Modeller.      
   
  
 
 
 
Figure 4.2: Three possible RBBP6 p53-binding domain models resolved by eThread-Modeller: [D–F] Represents the 
tertiary structures of Model-D, Model-E and Model-F respectively, the structures are ranked based on their Global distance 
test total scores (GDT_TS) and they only exhibit alpha-helices & coils/loops as shown in each model. The NH2 to C-
terminal positions of all models spans across from left to right.    
4.2 Sequence analysis and modelling quality assessment  
The RBBP6 p53-binding domain (p53BD) amino acid stretch was used as a query sequence in I-
TASSER for the prediction of structural properties (Figures 4.3-4.5). Both I-TASSER and eThread-
D E 
F 
GDT_TS: 0.5221 GDT_TS: 0.4730 
GDT_TS: 0.4692 
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Modeller models were then analysed and assessed for structural quality (Figures 4.7&4.8). In this 
section, structural properties (secondary structure prediction, solvent accessibility and B-Factor) 
generated by I-TASSER prior to the molecular modelling process are reported. Furthermore, the 
quality of Model-A and Model-D was assessed using Swiss-Model and ProSA (Protein Structure 
Assessment) web-applications. These applications added value to the statistical base to make confident 
statements regarding the quality of the models and enabled the selection of one that could better 
represent the RBBP6 p53BD.                 
4.2.1 Sequence analysis and properties prediction using I-TASSER    
 
I-TASSER predicted various properties of the submitted query sequence (RBBP6 p53BD sequence). 
The secondary structure corresponding to the query sequence was then determined together with the 
respective confidence scores (Figure 4.3). A helix-loop pattern feature which is like that illustrated by 
the 3D-models above was observed. However, this domain seems to be conserved at a tertiary structural 
level given the observed secondary and tertiary structural prediction differences. Solvent accessibility 
was also explored at a residue-per-residue level, to determine hydrophilic and hydrophobic regions. 
Noticeably, the helical regions including the 310-helix were shown to have solvent exposed residues 
meaning they are more likely to serve as potential hydration pockets (Figure 4.4).   
Figure 4.3: Secondary structure prediction by I-TASSER using the built-in Psipred algorithm: A high score 
(Conf.Score) implies higher confidence of secondary structural feature in that region, the key of the prediction is given 
below the sequences, i.e. Helices (Red), Strand (Blue), and Coil (Black).     
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Figure 4.4: Solvent accessibility prediction of the RBBP6 p53BD protein sequence: Regions with solvent exposed 
residues (hydrophilic) are potential hydration or functional sites, the top numbers represents a residue count in the sequence 
and the key is shown below the prediction scores.     
I-TASSER further predicted B-Factor values to indicate inherent thermal mobility of residues / atoms 
in the protein domain. This value is deduced from the threading template proteins retrieved from PDB 
in combination with the sequence profiles derived from sequence databases. Thus, the reported B-
factor corresponds to the normalised B-factor of the target protein (Figure 4.5), defined by the 
following equation;                 
B = 
(𝐵′− 𝑢) 
𝑠
 
Where B’ is the raw B-factor value, u and s are the respective mean and standard deviation of the raw 
B-factors along the sequence. The observed trend-line in figure 4.5 shows that there isn’t much 
fluctuation of atoms about their average positions. This indicates that the molecular dynamics of the 
RBBP6 p53BD is unlikely to affect modelling and docking calculations.      
Figure 4.5: Normalised B-factor predicted by the built-in ResQ (Residue Quality) algorithm: The blue trend-line 
indicate normalised B-factor values on a residue basis, the black and red dots below represents coils and helices respectively 
which is secondary structure prediction of the p53BD sequence, the key for the prediction is also given on top of the graph.   
Equation 4.1 
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I-TASSER modelling starts from the structure templates identified by LOMETS, which is a Meta-sever 
threading approach containing multiple threading programs. Each threading program can generate tens 
of thousands of templates alignments. I-TASSER then selects ten best temples from the LOMETS 
threading programs (Figure 4.6), these templates are of highest significance from each threading 
program as measured by the z-score (i.e. the difference between the raw and average scores in a unit 
of standard deviation). The top ten reported alignments or templates (in order of their ranking) in this 
section are from the following programs; 1. MUSTER 2. SPARKS-X 3. Neff-PPAS 4. MUSTER 5. 
SPARKS-X 6. Neff-PPAS 7. MUSTER 8. SPARKS-X 9. Neff-PPAS 10. SPARKS-X.              
Figure 4.6: The top 10 threading templates utilised by I-TASSER, represented along with their corresponding sequence 
alignment data. [Rank] Represents the threading templates used by I-TASSER, [Iden1] is the percentage sequence identity 
of the templates in the threading aligned region with the query sequence, [Iden2] is the percentage sequence identity of the 
whole template chains with query sequence, [Cov] represents the coverage of the threading alignment and is equal to the 
number of aligned residues divided by the length of query protein, [Norm.Z-score] is the normalized z-score of the 
threading alignments. Alignment with a Normalized z-score > 1 means a good alignment and vice versa, [Download Align] 
provides the 3D structure of the aligned regions of the threading templates. All residues are coloured in black; however, 
those residues in the template which are identical to the residue in the query sequence (Seq) are highlighted in colour. 
Colouring scheme is based on the property of amino acids, where polar are brightly coloured while non-polar residues are 
coloured in dark shade.  
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The eThread-Modeller program also retrieved templates from PDB prior the molecular modelling 
process (Appendix 5). In this section, top five templates retrieved by both servers are reported (Table 
4.1). When comparing, it is noted that there is no identity of the retrieved templates between these web-
severs. However, most of these protein templates are alpha-helical with segments of loop structures, 
which resembles the helix-loop nature of the above reported models. These findings are critical in 
confirming that the RBBP6 p53BD would fold to exhibit a helix-loop pattern configuration, and despite 
observed differences on retrieved templates the tertiary structural prediction remains consistent as 
observed from the reported models (Figure 4.1&4.2). This indicates that despite the use of any method 
in protein modelling the p53BD would more likely adopt this conformation. Therefore, this suggests 
that the helix-loop nature plays a critical role in stabilising the native state configuration of this domain 
(p53BD).          
Table 4.1 The top 5 RBBP6 p53BD templates retrieved by I-TASSER and eThread-Modeller from 
PDB (Protein Databank) 
I-TASSER (Iterative-Threading 
ASSEmbly Refinement)   
eThread-Modeller  
PDB ID Protein Name  PDB ID Protein Name  
2cse Major outer-capsid protein-mu1 4fmu Histone-lysine N-methyltransferase 
SETD2 
5df2 C.elegans FOG-3 BTG/Tob 
domain 
1e5w MOESIN (Helix), Isolated FERM 
domain 
4118 Sensor protein kdpD 5fm9 Neurogenic Locus Notch Homolog 
protein 1 
4n16 Carbonic anhydrase 2 2mbf Fork head domain containing protein 
2oto Streptococcus pyogenes M1 
protein 
4yyc Putative trimethylamine 
methyltransferase 
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4.2.2 Model quality assessment using Swiss-Model and ProSA 
 
Based on the six models generated by both web-applications (I-TASSER and eThread-Modeller), 
Model-A and Model-D seem to be the best representations of the RBBP6 p53BD. In this sub-section, 
further analyses of the two models using Swiss-Model and ProSA were conducted to evaluate their 
quality. These severs use four statistical parameters (i.e. Anolea, QMEAN, Dfire and ProSA z-score) 
that cover both local and global accuracy predictions, and one model which best represent the RBBP6 
p53BD was then selected for further docking studies.  
A comparative view of Model-A and Model-D in terms of both local (Anolea and QMEAN) and global 
(Dfire and ProSA) accuracy predictions is depicted in Figure 4.7 and 4.8. The local accuracy analyses 
in terms of favourable energy environments (Anolea) indicates the presence of negative energies in 
approximately all residues of Model-A (Figure 4.7A). This means that all these residues are in 
fovarable local environments with only one exception (SER53 (red arrow)) having a positive energy 
score. However, the Anolea graph of Model-D has significant differences especially for the first 40 
residues (Figure 4.8A). This graph indicates that about 9 residues are not in favourable energy 
environments, as shown by the red bars indicating positive energies (Figure 4.8A). The QMEAN 
(Qualitative Model Energy Analysis) is at an average energy range of 3-6 units throughout the query 
sequence for both models (Model-A & Model-D). This implies that there are no significant differences 
in terms of energy analysis between the models. Furthermore, the observed positive energy range on 
the QMEAN graphs indicates the absence of bad contacts between the residues.  
The Global accuracy analyses focused on two parameters, i.e. Dfire_energy and ProSA z-score. These 
statistics have critical differences when compared between Model-A and Model-D. The Dfire_energy 
score for Model-A is more negative (-85.28) than that of Model-D (-75.30), meaning that the RBBP6 
p53BD is likely to fold in a pattern resembling that of Model-A, as it’s closer to native state than 
Model-D. As previously mentioned, the ProSA-web measures the overall quality of the model and 
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produces a z-score in comparison to all experimentally determined crystal structures in current PDB. 
Here, both models seem to fall within the NMR region (blue). However, models of similar size seem 
to contain more negative z-scores in a range of -8 to 0. Implying that the more negative is the model’s 
z-score at this size (111 amino acids) the more it is likely to resemble native state. The above results 
further indicate that Model-A (ProSA z-score = -1.92) is closer to native state than Model-D (ProSA 
z-score = -1.08), hence it is the best possible representation of the RBBP6 p53BD to be utilised for 
further docking studies.                              
 
 
                 
 
 
 
 
                 
     
 
 
 
 
 
 
Figure 4.7: Structural quality assessment of Model-A: Resolved using Swiss-model & ProSA web-severs, [A] Depicts 
two local statistics i.e. ANOLEA and QMEAN represented by the top bars (green & red) and the red trend-line respectively. 
The Dfire_energy is associated with global accuracy of the model. [B] ProSA z-score statistics examines the global accuracy 
by determining where the model’s z-score sits in comparison to all structures in current PDB (Protein Data bank), thus the 
black dot on the graph represents the region at which the model is located relative to all crystallised proteins. The key to 
the graph is provided on the top-right corner.         
 
ProSA z-score: -1. 92  
B 
p53BD model 
Key 
Positive energy 
A 
Dfire_energy: -85.28  
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  Figure 4.8: Structural quality assessment of Model-D: Resolved using Swiss-model & ProSA web-severs, [A] Depicts 
two local statistics i.e. ANOLEA and QMEAN represented by the top bars (green & red) and the red trend-line respectively. 
The Dfire_energy is associated with global accuracy of the model. [B] ProSA z-score statistics examines the global accuracy 
by determining where the model’s z-score sits in comparison to all structures in current PDB (Protein Database), thus the 
black dot on the graph represents the region at which the model is located relative to all crystallised proteins. The key to 
the graph is provided on the top-right corner.                                 
 
4.3 Binding site prediction using FTSite: Binding site prediction server 
 
Prior to receptor-based molecular docking binding sites of all three RBBP6 domains (Figure 4.9-4.11) 
were determined. This is critical during Grid generation as it specifies residues facilitating the binding 
co-ordination between the pocket and a given potential drug-candidate. Thus, for successful docking 
studies binding site prediction is necessary. FTSite binding site prediction server was used, and it 
predicted three potential binding pockets in all domains. These binding pockets are represented with 
putative ligand binding sites (net-like structures) and their respective residues.                    
Dfire_energy: -75. 30 
 A Positive energy 
p53BD model   Key 
ProSA z-score: -1. 08  
 B 
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4.3.1 Binding sites for the Domain With No Name (DWNN)  
 
Three potential binding sites of the DWNN domain were identified (Figure 4.9). These findings would 
help in discovering potential drugs (agonist / antagonist) through docking experiments. Hydrophilic 
domains are potential binding or functional sites, meaning that more hydrophobic regions are difficult 
to target with small organic compounds. Thus, site 1 of the DWNN below would be more efficiently 
targeted based on the high hydrophilic state it possesses in comparison to the other two sites (site 2 and 
3). The DWNN domain has been implicated in mitotic apoptosis, however, there has not been any 
records of structural work reported. Thus, three docking studies for all sites were performed in search 
of potential lead compounds from the zinc drug database (Zdd).                
 
    
 
                                                            
 
 
 
 
 
 
 
 
 
Figure 4.9: Binding site prediction for the Domain With No name (DWNN): Showing three potential drug-binding 
pockets in pink, blue and golden brown, these were resolved by FTSite and viewed using PyMol. The number of non-
bonded interactions with low energy clusters increases from site 3, site 2 and site 1. The residues below also indicate that 
hydrophilicity increases from site 3, site 2 and site 1. Stick models represent the residues involved in binding.   
 
                    Site 1                              Site 3                                 Site 2     
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4.3.2 Binding sites for the RING Finger domain  
 
The RING Finger domain adopts a homodimeric structure in which the interface contains hydrophobic 
residues similar to U-boxes (Kappo et al., 2012). This hydrophobic interface has intrinsic E3 Ligase 
activity like MDM2 the prototypical negative regulator of p53. Three binding sites on the RING Finger 
were determined. Interestingly, site 3 (blue) is located at the exact interface between the monomers and 
is characterised by hydrophobic residues (Figure 4.10). Since RBBP6 can bind both p53 and pRB, this 
site is likely to promote ubiquitination and subsequent proteasomal degradation of these pro-apoptotic 
proteins. Therefore, only one docking job was performed in search for potential drugs that can inhibit 
the E3 ligase catalytic site (site 3) and re-activate p53 and pRB levels in cancer cells.  
 
 
 
 
 
 
 
 
                   
Figure 4.10: Binding site prediction for the RING Finger domain: Showing three critical binding pockets (Site 1, Site 
3, Site 2) in pink, blue and golden brown respectively. These were resolved by FTSite and viewed using PyMol. The number 
of non-bonded interactions with low energy clusters increases from site 3, site 2 and site 1. The residues below also indicate 
that hydrophilicity increases from site 3, site 2 and site 1 and the A & B represent the two monomers on which the residues 
are located. Stick models represent the residues involved in binding.         
                     Site 1                            Site 3                             Site 2     
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4.3.3 Binding sites for the p53-binding domain (Model-A)  
 
Mode-A was selected as the best representation of the RBBP6 p53BD. Therefore, it was used in binding 
site prediction and further docking experiments. Three potential binding sites were identified in this 
domain and site 1 was selected for docking (Figure 4.11). Due to its high hydrophilicity, site 1 is likely 
the most potential binding region for p53. The p53BD adopts a helix-loop pattern structural fold and 
the helix regions are more likely to serve as potential binding sites (i.e. site 1 and site 3), with only site 
2 (yellow) being an exception as it is located within the loop region (Figure 4.11). This confirms the 
results obtained in section 4.2.1 (Figure 4.3&4.4).             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Binding site prediction for the RBBP6 p53-binding domain (Model-A): Showing three critical binding 
pockets in yellow, golden brown and blue respectively, resolved by FTSite and viewed using PyMol. The number of non-
bonded interactions with low energy clusters increases from site 3, site 2 and site 1. The residues below also indicate that 
hydrophilicity increases from site 3, site 2 and site 1. Stick models represent the residues involved in binding.    
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4.4 Virtual screening & Molecular docking using Schrödinger-Maestro v10.7: 
Glide SP 
 
Molecular docking studies were performed to determine potential lead compounds for RBBP6. The 
screened Zinc drug database (Zdd) contains 2924 readily available FDA approved compounds. In the 
present study, docking calculations were performed onto all three domains of RBBP6 (Figure 4.12-
4.17). This was achieved using the Schrödinger-Maestro v10.7: Glide SP, targeting selected binding 
pockets such as those known to bind cell-cycle regulatory proteins. For comparison purposes, a further 
docking calculation onto the MDM2 p53-binding domain was performed (Figure 4.18). Additionally, 
figure 4.19 representing binding posses of the p53 peptide and the most potent nutlins (Nutlin-2 and 
MI-219) is shown and compared to the first MDM2 binding lead compound (Ezetimibe).      
During the docking process, the Glide standard precision algorithm generated over two thousand 
different lead compounds with multiple posses per each docking run. Therefore, the generated outputs 
contained approximately over two thousand lead compounds in each site. Analyses focusing on the 
docking scores, Glide scores and Glide emodel scores of the lead compounds enabled selection of the 
top 3 leads in each targeted site (Table 4.2).                       
4.4.1 (+)-Catechin binds into the Domain With No Name (DWNN) binding pocket 
 
The DWNN was docked in all three sites. Among these binding pockets site 1 is the most hydrophilic 
and thus the most potential binding site. Therefore, here only the first binding pocket (site 1) bound to 
(+)-catechin is reported (Figure 4.12). Interestingly, a phosphate molecule was observed to tightly bind 
on site 2, suggesting that this may be a phosphorylation site on DWNN.  The site 1 lead compound, 
(+)-catechin is an antioxidant, a type of natural phenol that serve as a plant secondary metabolite and 
belong to a group of flavanols. Catechins are the major components of green tea extracts and possess 
several properties that tend to have wide implications in disease and lifestyle conditions, such as 
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cardiovascular pathology, cancer, arthritis as well as obesity (Reygaert, 2017). Here, a very good 
binding mode consisting of four hydrogen bonds (yellow dotted-lines) and possible hydrophobic 
interactions is observed between (+)-catechin and DWNN (Figure 4.12A).  There is also a collection 
of good steric contacts (green dotted-lines) suggesting a stereo-chemically feasible binding 
configuration of (+)-catechin to DWNN (Figure 4.12B). This finding suggests that the catechins’ 
tumour inhibitory effect is likely via RBBP6 DWNN, indicating that RBBP6 may be involved in their 
pharmacologic activity.              
       
 
 
 
 
 
 
 
 
 
 
Figure 4.12: The first lead compound ((+)-Catechin) docked into site 1 of the DWNN: [A] Shows (+)-Catechin 
(ZINC00119985) and DWNN interaction, hydrogen bonds are coloured in yellow dotted-lines and the presence of 
hydrophobic residues (ILE69, LEU68, ALA67, LEU31, PRO70) within the drug vicinity indicates the possibility of 
hydrophobic interactions. The binding site is largely composed of β-sheets and loop structures (yellow, blue & cyan) [B] 
Represents a residue property surface together with a network of good steric contacts between the (+)-Catechin-DWNN 
complex.  
The chemical structure of (+)-catechin is composed of several water-soluble regions such as the 
hydroxyl groups (-OH) which makes it a good lead compound (Figure 4.13). This compound possesses 
two benzene rings and a hydroxyl group attached to carbon 3 of the dihydropyran heterocycle. There 
are two chiral centres on carbon 2 and 3 of the molecule which makes four diastereoisomers, two in 
trans-configuration (catechin) and two in cis-configuration (epicatechin) (Figure 4.13A).  
 A  B 
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Among the catechins, (+)-catechin is the most common, but it has a stereoisomer (-)-catechin. Glide 
SP (Standard precision) also computed a ligand interaction diagram of the (+)-Catechin-DWNN 
complex showing all residues at 3Å axis within the binding pocket (site 1) (Figure 4.13B). The presence 
of ionic groups also suggests the possibility of electrostatic and van der Waals interactions, which 
would greatly contribute towards the binding affinity of the complex.        
   
 
 
 
 
 
 
 
Figure 4.13: Structural composition and interaction analysis of (+)-Catechin with DWNN: [A] Shows a ball and stick 
model of (+)-Catechin which is a potential DWNN domain agonist or antagonist, the red, white and grey spheres represents 
Oxygen (O2), hydrogens (H), and Carbons (C) respectively, chiral centres are labelled 2 & 3 [B] Demonstrates a 2D ligand 
interaction diagram with a collection of nearby hydrophobic residues as well as four hydrogen bond coordination to LEU68, 
GLU60, ASN66 and GLU61. 
 
4.4.2 Plerixafor binds into the RBBP6 RING Finger E3 Ligase site (site 3) 
 
Plerixafor is an immunostimulant used to mobilise hematopoietic stem cells in cancer patients. This 
drug is currently utilised synergistically with granulocyte colony-stimulating factor (G-CSF) to release 
hematopoietic stem cells from the born marrow into the peripheral blood for collection and subsequent 
autologous transplantation in Non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) patients 
(Uy et al., 2008). Plerixafor exhibits an antagonistic effect to the CXCR4 chemokine receptor binding 
A B 
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to three acidic residues (ASP171, ASP262 and GLU288) within the pocket and thus blocking binding 
of its cognate ligand, stromal cell derived factor-1 (SDF-1α).  
In the current study, this drug binds tightly (docking score -7.756) to the E3 ligase site of the RING 
Finger domain implicating RBBP6 as a potential off-target from CXCR4 (Figure 4.14).  This finding 
suggests that plerixafor can also block the E3 ligase activity of RBBP6. The figure 4.14 below depicts 
a range of bonding networks such as hydrogen bonds (yellow dotted-lines) and possible hydrophobic 
interactions, stipulated by the presence of hydrophobic residues (VAL304, PRO273, LEU309, and 
ALA308) near the drug within the binding pocket of the RING Finger domain (site 3) (Figure 4.14A). 
The collection of good steric contacts (green dotted-lines) below also affirms the stereochemical 
feasibility of the complex, indicating no steric clashes or bad contacts between the drug and 
neighbouring residues (Figure 4.14B).   
 
 
 
 
 
 
 
 
 
 
 Figure 4.14: The first lead compound (plerixafor) docked into site 3 of the RING Finger domain (E3-Ligase site): 
[A] Shows the plerixafor-RING Finger’s hydrogen bonds and hydrophobic interactions, this drug is bound within the 
interface just below the triple-stranded β-sheets (light blue & yellow). Helices and loops are shown in green within the drug 
vicinity [B] Depicts a constant surface along with a network of good steric contacts (green dotted-lines) for the Plerixafor-
RING Finger domain complex. 
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Plerixafor adopts a bicyclam structure with two symmetrical rings separated by a para-substituted 
benzene ring (Figure 4.15). The bulkiness of this lead compound enables it to fill-up the entire active 
site volume of the hydrophobic interface on the catalytic site, suggesting that it exerts complete 
inhibition of the E3 ligase activity. The ligand interaction diagram below provides a picture of how 
nearby residues (at 3Å axis) interact with plerixafor (Figure 4.15B). These results indicate that four 
hydrogen bonds (purple dotted-lines) are formed and there is a high density of hydrophobic residues 
within the drug vicinity. Furthermore, the tight binding of Plerixafor-RING Finger domain complex is 
facilitated by the fact that plerixafor is also highly hydrophobic in its chemical nature. The positively 
charged nitrogen ions (N+) on both rings indicate the possibility of ionic or electrostatic interactions, 
perhaps contributing to high binding affinity of the complex.  
 
 
 
 
 
 
 
 
Figure 4.15: Structural composition and interaction analysis of plerixafor with the RING Finger domain: [A] Shows 
a ball and stick model of plerixafor (ZINC22443609) a potential RBBP6 RING Finger domain inhibitor, the blue, green 
and white sticks represents nitrogen (N), carbons (C), and hydrogens (H) respectively [B] Demonstrates a 2D ligand 
interaction diagram with a collection of nearby hydrophobic residues as well as four hydrogen bond coordination (purple 
arrows) to CYS274, PRO273, and ASP303.    
 
 
 
  A  B 
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4.4.3 Nicotinamide adenine dinucleotide (NADH) docks into the RBBP6 p53-binding 
domain 
 
NADH is a well-studied co-enzyme produced in many cellular contexts, especially during glucose 
metabolism and is found in all living cells. Since it exhibits both oxidising and reducing properties it 
is involved in redox reactions during metabolism. This means that NAD+ (oxidising agent) accept 
electrons from other molecules and become reduced to form NADH (reducing agent), which can then 
be used as a reducing agent to donate electrons to the electron transport chain occurring in the 
mitochondria. NADH is in turn oxidised by the electron transport chain which pumps protons across 
the membrane to generate ATP through oxidative phosphorylation (OXPHOS).  
In the present study, NADH is observed to bind the RBBP6 p53-binding domain (p53BD) forming 
four hydrogen bonds and electrostatic interactions with the p53BD hydrophilic pocket (Figure 4.16). 
The tight binding of NADH to the p53BD is further depicted by the collection of good steric contacts 
(green dotted-lines) with no bad clashes between the co-ordinating residues (Figure 4.16B). These 
findings implicate NADH as a good lead compound that can be utilised as a scaffold to develop drugs 
which could disrupt the RBBP6-p53 interaction.         
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Figure 4.16: The first lead compound (NADH) docked into site 1 of the RBBP6 p53BD: [A] Shows the NADH 
(ZINC53682927) and p53BD interaction, hydrogen bonds are coloured in yellow dotted-lines and hydrophilic interactions 
are expected since the first binding site (hydrophilic) was targeted in this case. The binding site is within the helix region 
of the domain (greenish-yellow) [B] Depicts a constant surface along with a network of good steric contacts (green dotted-
lines) for the drug-receptor complex. 
The NADH structure is composed of two nucleotides (nicotinamide and adenine) joined together 
through their phosphate groups, thus it’s referred to as a dinucleotide (Figure 4.17A). The presence of 
these phosphate groups provides negative charges and thus determine the overall net-charge of NADH. 
This further indicates the possibility of ionic interactions which greatly contributes to the docking score 
and thus binding affinity of the interacting complex. The ligand interaction diagram was measured at 
3Å axis around the drug and shows four hydrogen bonds co-ordinated by nearby residues (Figure 
4.17B).    
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Figure 4.17: Structural composition and interaction analysis of Nicotinamide adenine dinucleotide (NADH) with the 
RBBP6 p53BD: [A] Shows a ball and stick model of NADH (ZINC53682927) a potential RBBP6 p53-binding domain 
inhibitor, the maroon, pick, blue, brown and white sticks represents phosphates (P), oxygen (O2), nitrogen (N), carbon (C) 
and hydrogen (H) respectively [B] Demonstrates a 2D ligand interaction diagram with a collection of nearby residues as 
well as four hydrogen bond (red arrows) coordination to ASP44 (red), and LYS41(blue). 
4.4.4 Ezetimibe (Zetia) docks into the MDM2 p53-binding domain (hydrophobic pocket)   
 
Multiple studies have shown that the MDM2 hydrophobic cleft binds the p53-transactivation domain 
and thus targeting p53 for proteasomal degradation. For comparison purposes, the Zinc drug database 
was docked into the MDM2 p53-binding domain to determine if there is any match among the lead 
compounds picked-up by the RBBP6 p53-binding domain, and thus whether there are some expected 
off-target effects. Here, ezetimibe was observed to bind the MDM2 hydrophobic cleft with high affinity 
(with a docking score of -7.885) and no lead compound matches were noted between these two proteins 
(MDM2 and RBBP6) (Figure 4.18).    
Ezetimibe is a drug that falls within a class of lipid-lowering compounds. This drug is currently used 
to selectivity inhibit intestinal absorption of cholesterol and related phytosterols from dietary and 
biliary sources. Ezetimibe has been shown to have a direct impact on the reduction of plasma total 
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cholesterol concentrations in several pre-clinical models (Catapano, 2001). This is because the drug 
inhibits cholesterol absorption from the small intestines, thus reduces the amount of cholesterol 
available to liver cells. This forces the cells to absorb cholesterol from the circulatory system, hence 
lowering total plasma cholesterol concentration.  
Ezetimibe undergoes glucuronidation (addition of glucuronic acid) to a single metabolite, and then it 
targets and blocks the Niemann-Pick C1-like 1 (NPC1L1) protein which keeps cholesterol in the 
intestinal lumen for excretion. The glucuronidation metabolite form of ezetimibe is more water-soluble 
and binds NPC1L1 protein with higher affinity than ezetimibe to prevent cholesterol absorption from 
the gastrointestinal tracts. Interestingly, through docking experiments, the present study has determined 
that ezetimibe forms a single hydrogen bond with VAL93 (just like the p53 peptide does with TRP23) 
and mimics all three key residues of p53 (i.e. TRP23, LEU26, and PHE19) upon binding the MDM2 
hydrophobic pocket (Figure 4.18A and 4.19A).  
The collection of good steric-contacts (green dotted-lines) upon binding conforms the stereochemical 
feasibility and high affinity of the complex (Figure 4.18B). The structural composition of ezetimibe is 
known as monobactam and comprises the beta-lactam ring alone or fused to another ring (Figure 
4.18C). It belongs to a class of organic compounds under the organoheterocyclic compounds 
superclass. This drug is currently used in patients suffering from hyperlipidaemia or 
hypercholesterolemia, but the ligand interaction diagram below shows that ezetimibe tightly binds the 
MDM2-p53BD with hydrophobic and ionic interactions at 3Å axis around the drug (Figure 4.18D). 
This finding is likely to have significant impact in cancers with high MDM2 expression. 
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Figure 4.18: The first compound (Ezetimibe) docked into the p53-binding domain of MDM2 (hydrophobic pocket): 
[A] Shows Ezetimibe and MDM2 interaction, a single hydrogen bond with VAL93 (yellow dotted-line) and possible 
hydrophobic interactions are observed. [B] Depicts a residue property surface along with a network of good steric contacts 
(green dotted-lines) of the Ezetimibe-MDM2 complex. This surface representation shows the pocket-like nature of the 
binding site and how Ezetimibe accurately mimics the three critical p53 binding residues (PHE19, TRP23, and LEU26). 
[C] Shows a ball and stick model of Ezetimibe (ZINC03810860) a potential MDM2 p53-binding domain inhibitor, where 
the white, green, blue and red spheres represent hydrogen (H), fluorine (F), nitrogen (N) and oxygen (O2) respectively. [D] 
Demonstrates a 2D ligand interaction diagram with a collection of nearby residues and a single hydrogen bond (purple 
arrow) co-ordination to VAL93 (green).  
The observed binding mode affirms an accurate inhibition of p53 binding, thus should prevent the 
formation of MDM2-p53 complexes. A comparative view of both figure 4.18 and 4.19 shows that 
Ezetimibe is not structurally like the well-known nutlins (Nutlin-2, Nutlin-3a and MI-219), but seem 
A   B 
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to mimic the p53 peptide upon binding the MDM2 hydrophobic pocket more accurately than them 
(Figure 4.18 and 4.19). However, this does not negate the fact that nutlins are very good inhibitors of 
the MDM2-p53 interaction that have been thoroughly studied thus far, but rather presents another 
promising class of compounds which interacts with MDM2 in a similar function.       
   
Figure 4.19: Structural binding modes of the p53 peptide (pdb:1YCR), the cis-imidazoline analog, Nutlin-2 
(pdb:1rv1), and the spiro-oxindole analog MI-219 to MDM2: [A] Shows the p53 transactivation domain residues that 
are very critical for the MDM2-p53 interaction in stick representation, Nutlin-2 is shown in ball and stick models with 
carbons in cyan, nitrogen in blue, oxygen in red, and bromine in brown. The predicted binding of MI-219 to MDM2 is 
shown with carbons in cyan, nitrogen in blue, oxygen in red, fluorine in light blue, and chlorine in green. The surface 
representation of MDM2 in each case is shown with carbons in gray, nitrogen in blue, oxygen in red, and sulfur in yellow. 
Hydrogen bonds are depicted with yellow lines. [B] Shows chemical structures of Nutlin-3a and MI-219, the two potent 
and specific small-molecule inhibitors of the MDM2-p53 interaction (Adapted from: Shangary et al., 2009). 
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The RBBP6 domains have shown to bind multiple potential drugs upon virtual screening of the zinc 
drug database (Zdd). This database was chosen primarily based on two critical parameters, namely; 
database size and FDA approval. Therefore, the small zinc drug database size of 2924 compounds 
enabled that all six docking studies are performed with high quality, high processing power, and 
maximum storage of outputs. Hence the entire process was also not financially expensive. Furthermore, 
the used of an FDA approved database would speed-up the optimisation process since the obtained 
lead compounds are already “drugs” themselves (i.e. they already possess drug-like properties) 
targeting different proteins.        
The targeted dataset has not been previously screened for RBBP6, thus these drugs could serve as 
activators or inhibitors depending on the domain and site at which they bind. In Glide, the Zdd was 
firstly prepared and generated compounds about double its original size (from 2924 to 4909). The 
newly generated compounds contained different possesses of the original dataset to account for 
possible stereoisomers and had adopted a lowest energy possible 3-dimensional configuration suitable 
for docking. This was to further permit ligand flexibility during docking whilst the receptor is kept 
rigid, and a top 3 of over thousand compounds were selected in each domain (Table 4.2). Shown in 
this chapter is raw A, which are the first lead compounds in each of the RBBP6 domains. However, all 
top three are good lead compounds of RBBP6 that could serve as scaffolds for further optimisation 
depending on the domains at which they bind and its context in cancer therapy.             
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Table 4.2: Top three lead compounds of RBBP6 shown along with their binding energies.  
 
Drugs  Domain With No Name (DWNN) RING Finger domain p53-binding domain  
 
 
 
 
  A 
 
 
 
 
 
 
 
 
 
 
 
 
  B 
 
 
 
 
 
 
 
 
 
 
 
   C 
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RBBP6 is a eukaryotic multifunctional protein and is implicated in diverse cellular functions such as 
nucleic acid metabolism, cell cycle regulation (Scott et al., 2003 and Kappo et al., 2012), as well as 
carcinogenesis as it associates with both p53 and pRB which are key cell cycle regulators largely linked 
to carcinogenesis (Witte and Scott, 1997). Overexpression of RBBP6 in cervical cancer also indicated 
that it positively influences the S-phase of the cell cycle, and ultimately promotes cell proliferation. 
Conversely, the down regulation of RBBP6 is associated with apoptosis (Moela et al., 2016). These 
findings suggest that RBBP6 may be a plausible target for cancer therapy (Ntwasa, 2008). 
 In this study, a computational approach was taken to determine whether RBBP6 is druggable. The 3-
dimensional structures of three RBBP6 domains (DWNN, RING Finger and p53-binding domain) were 
targeted as potential drug binding sites. Molecular docking studies were conducted using the zinc drug 
database. Three-dimensional structures of the DWNN and the RING Finger domain are already known 
but the p53-binding domain tertiary structure has not been reported.  In this study, the p53-binding 
domain was modelled using I-TASSER and eThread-Modeller prior the ligand docking process (Figure 
4.1&4.2). Three binding sites were predicted using FTSite, and docking studies produced 3 potential 
drugs, namely; (+)-catechin, plerixafor and nicotinamide adenine dinucleotide binding to DWNN, 
RING Finger and the p53BD respectively. Two of these are known drugs but the one binding to the 
p53BD is a novel drug considered as lead compound worthy for further development. These findings 
suggest that RBBP6 can bind small molecular agonist or antagonist, implying that it is druggable.  
For comparison, a docking study was conducted targeting the MDM2 p53-binding domain. This was 
to determine if there are any similar molecules binding to the p53-binding domains of RBBP6 and 
MDM2. The MDM2 p53BD binds to Nutlins which are in clinical trials for treatment of certain cancers 
(Burgess et. al., 2016). 
   CHAPTER FIVE: DISCUSSION   
                                                                                                                                                        
 
54 Charmy Starnod Twala, Master of Science in biochemistry and bioinformatics  
The Zdd used for docking does not contain Nutlins, however it has a collection of piperazine 
compounds (class of nutlins) which did not show any binding with MDM2. The lack of matches on the 
retrieved lead compounds between these proteins confirms that there is no link or similarity between 
them.                                  
5.1 The I-TASSER model (Model-A) seem to be the best possible representation of the 
RBBP6 p53-binding domain.   
 
The RBBP6 p53-binding domain was modelled using I-TASSER, which attempts to efficiently mimic 
in vivo molecular dynamics, by using a hierarchal approach that consistently drives the threading 
alignments closer to native state. The models generated by I-TASSER are represented together with 
their local accuracy prediction graphs which clearly stipulates structural differences between the 
predicted models and native state, at a residue-per residue basis (Figure 4.1(1-3)).  
In this study, it has been observed that Model-A possess minimal deviation from native state as 
compared to all models generated by I-TASSER. Furthermore, this model constitutes a c-score of - 
2.57, which is a good score higher than that of the other I-TASSER models. However, this c-score is 
less than -1.5 indicating that the global topology of Model-A still needs further refinements. This might 
be because, firstly, the domain was modelled separately from the rest of the protein chain, thus losing 
the interaction influence and molecular dynamics of the neighbouring domains. Secondly, the 
modelling process assumed that the p53-binding domain functions as a monomer, whilst homo or 
hetero-dimerization is also possible, and this could change the binding interface appreciably.      
These results were corroborated by the models generated by eThread-Modeller because there is 
consistency of the helix-loop pattern generated, indicating that the native configuration of the domain 
is likely composed of helices and coil / loop structures with no beta sheets. Altogether, using molecular 
modelling, these results suggests that the RBBP6 p53BD adopts a native helix-loop pattern structural 
fold.          
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Furthermore, both I-TASSER and eThread-Modeller models (Model-A and Model-D) were assessed 
for structural quality using Swiss-Model and ProSA (Protein Structure Assessment) web-servers. 
Quality assessment was based on various statistical parameters namely; Anolea, Dfire, QMEAN, 
ProCheck, and ProSA Z-score. These parameters cover both local and global quality assessments. The 
Anolea graph evaluates the “Non-Local Environment” (NLE) of each heavy atom in the molecule, and 
in this instance Model-A constitutes a range of green bars (negative energy values) in the entire Anolea 
graph despite a single red bar (SER53) (Figure 4.7A). This implies that 99.5% of residues in this model 
are in favourable energy environments. The Dfire_energy score of the model is also quite negative (-
85.28), implicating that the model is very close to native state (Figure 4.7A). The ProSA Z-score is -
1.95, which places the model at an NMR region of previously crystallised protein structures. Therefore, 
these results confirm that the Model-A is quite closer to native state, and thus depicts minimal deviation 
to known crystallographic structures as compared to others (the four and five models generated by I-
TASSER and eThread-Modeller respectively).  
Structural quality assessment was also performed to the first model (Model-D) generated by eThread-
Modeller. The Anolea graph results have further demonstrated the presence of unfavourable energy 
residues, thus implying that there are 91.9% residues in the model occupying favourable energy 
environments. This percentage has been significantly reduced when compared to the 99.5% in Model-
A, the assumption is that the other four models generated by eThread-Modeller would even constitute 
a lesser percentage of residues with favourable energy environments. The DFire energy score is also 
less negative when compared to that of Model-A, meaning that Model-D is not that closer to native 
state in comparison. Therefore, it appears statistically feasible to propose that Model-A is the best 
possible representation of the RBBP6 p53-binding domain. However, its global topology would still 
need further refinements as previously stated.               
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5.2 The binding of catechins to the RBBP6 DWNN may have positive implications in 
cancer 
 
Catechins have numerous health benefits although its mechanism of action is not currently well-
understood. It is known, however, that catechins ((2R, 3S)-2-(3, 4-dihydroxyphenyl)-3,4-dihydro-2H-
chromene-3,5,7-triol) are the major components of green tea, and several studies (in vitro, in vivo and 
epidemiological studies) have shown that consumption of green tea may significantly reduce risk to 
cancer (Khan et al., 2007). These green tea extracts (epigallocatechin-3-gallate (EGCG)), have been 
further shown to inhibit tumour invasion and angiogenesis which are crucial for tumour growth and 
metastasis (Lecumberri et al., 2013).                
Camellia sinensis is a plant derived beverage that is largely consumed as green tea in Asia, parts of 
North Africa, the United states and Europe (Khan et al., 2007; Chacko et al., 2010). Therefore, a very 
limited number of individuals with cancer (especially skin, lung, prostate, breast, Liver and 
Gastrointestinal cancers) is reported in these parts of the world compared to other continents and 
countries. Consequently, beneficial effects on human health are attributed to green tea (Khan et al., 
2007).    
 In this study, using molecular docking, the two trans-stereoisomers ((+)-catechins and (-)-catechins) 
of catechin are observed to tightly bind the RBBP6 DWNN. The (+)-catechin binds more tightly (Glide 
energy: -34.418, Glide emodel: -47.466, docking score: -6.784) to the domain than its corresponding 
stereo-isomer, (-)-catechins (Glide energy: -35.265, Glide emodel: -48.361, docking score: -6.588) 
(Figure 4.12). Thus, making it the top lead compound (within the Zinc drug database) upon binding 
the RBBP6 DWNN. These are interesting findings since catechins are known to have tumour inhibitory 
effects. 
Knock down studies in human cancers have revealed that tumour progression is related to increased 
levels of DWNN (Mbita et al., 2011). Indicating that this domain is involved in mitotic apoptosis, as 
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its over-expression led to an increased G2/M cell cycle arrest (Mbita et al., 2011). Therefore, if the 
tumour inhibitory effects of catechins are via the RBBP6 DWNN, they could serve as activators 
(agonists) of this domain.                             
5.3 Plerixafor binds to the catalytic site (hydrophobic interface) of RBBP6 
 
Before its current use as an immunostimulant to increase white blood cell count by significantly 
increasing the number of hematopoietic stem cells (HSC) circulating in the peripheral blood, plerixafor 
(1, 4-Bis ((1, 4, 8, 11-tetraazacyclotetradecan-1-yl) methyl) benzene) was primarily designed for HIV-
infection therapy. This is because it targets the CXCR4 chemokine receptor, which is a co-receptor for 
Human Immunodeficiency virus (HIV-1) entry into the cell. HIV-1 enters the cell via CD4 which is 
the main receptor on the cell surface, however CXCR4 and CCR5 serve as co-receptors that take-up 
T-lymphotropic (T-tropic) and M-lymphotropic (M-tropic) HIV-1 strains respectively (Feng et al., 
1996; Wu el at., 1996).  
During asymptomatic stages of the disease, the M-tropic HIV-1 strains enters the cell via CCR5 co-
receptors (Alkhatib et al., 1996), and the T-tropic HIV-1 strains targeting the CXCR4 eventually 
replaces them later as they are associated with rapid disease progression (Cheng-Mayer et al., 1988). 
Therefore, plerixafor would target the CXCR4 and block the HIV-1 co-receptor function. Thus, it was 
the first drug with antagonistic effect to CXCR4 to enter clinical trials for the treatment of HIV 
infection. Unfortunately, it was found to exhibit cardiac toxicity before further clinical development 
could be performed. 
However, this led to the identification of an unexpected side effect and was later hypothesised that 
plerixafor may find its application on hematopoietic stem cell (HSC) mobilisation for the purposes of 
peripheral blood stem cell transplantation (PBSCT) (De Clercq, 2009). Thus, plerixafor has been 
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approved recently (2009) by the European Medicines Agency (EMEA) as a drug to help patience with 
lymphoma and multiple myeloma since their cells poorly mobilise.  
In the present study, molecular docking studies show that plerixafor binds tightly to the RBBP6 RING 
Finger domain (Figure 4.14). This observed binding mode possesses good energies (Glide energy: -
60.179, Glide emodel: -121.038, docking score: -7.756), suggesting that RBBP6 might be involved in 
hematopoietic stem cell mobilisation. Altogether, these results suggest that the cancer application of 
plerixafor may be via the RING Finger domain and can have positive implication in cancer patients 
with high RBBP6 expression (such as cervical, lung, breast, colorectal, prostate, head & neck as well 
as pencreatic cancers). This binding mode suggests a complete inhibition of the RBBP6’s E3 ligase 
activity, thus likely to reactive intracellular levels of pro-apoptotic proteins, such p53 and pRB. RBBP6 
contains p53 and pRB binding domains, hence these proteins are likely substrates ubiquitinated by the 
RING Finger domain.    
5.4 Nicotinamide adenine dinucleotide (NADH) binds the RBBP6 p53-binding 
domain possibly inhibiting p53     
 
Using Model-A, potential p53 inhibitors were investigated through docking experiments. Interestingly, 
the co-enzyme Nicotinamide adenine dinucleotide (NADH) was determined and shown to bind this 
domain with high affinity (Figure 4.16). This binding affinity was estimated using the docking score 
to give an indication of the bond-strength between NADH and the RBBP6 p53BD, and a docking score 
of -6.136 implying high affinity was observed (Table 4.2).  
In metabolism, NADH is involved in redox reaction and exhibits both oxidizing and reducing agent 
species in solution. Although this is a well-studied molecule its binding to RBBP6 is yet to be reported. 
This study demonstrated that NADH binds RBBP6 with good binding energies (Glide energy: -47.387, 
Glide emodel: -61.698, docking score: -6.136) making it the best molecule (within the zinc drug 
database) that binds the p53-binding domain of RBBP6 (Table 4.2). Therefore, this finding sets-up an 
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excellent premise on which pre-clinical drug inhibitors could be developed, thus implicating NADH 
as a good lead compound that could be optimised to block RBBP6-p53 interaction leading to the re-
activation of p53 levels in cancer cells. The inhibition of RBBP6-p53 binding leads to the stabilisation 
of p53 in cancer cells consequently promoting p53-dependent cell cycle arrest or apoptosis. This study 
has identified a possible inhibitor for the RBBP6 p53BD, and future studies optimising this lead 
compound (in the context of blocking the formation of RBBP6-p53 complexes) may prove useful in 
cancer therapy.       
5.5 RBBP6 probably binds independently to p53 on a different site compared to the 
transactivation domain targeted by MDM2  
 
Both RBBP6 and MDM2 are well-known cell cycle regulators as they bind and promote proteasomal 
degradation of p53. In the present study, sequence alignment data of the p53BDs revealed very poor 
similarity and molecular docking studies further demonstrated major differences of the p53-binding 
pockets together with their retrieved lead compounds (Figure 4.16&4.18). This suggests that RBBP6 
and MDM2 bind p53 at different sites. 
It is important to note that these findings do not negate those of other studies that RBBP6 (also known 
as PACT) may act as a scaffold promoting the assembly of p53 and MDM2 (also known as HDM2) 
proteins (Li et al., 2007). These results only imply that the binding is different and independent, but 
RBBP6 can still bind both proteins and facilitate their interaction independent of MDM2. Altogether, 
this finding suggests that the formation of MDM2-p53 complexes relies on the availability of RBBP6, 
whilst RBBP6-p53 complexes does not need MDM2. Interestingly, this finding enables for an 
increased specificity upon optimisation of drugs targeting the RBBP6 p53BD.  
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5.6 Ezetimibe (Zetia) accurately mimics p53 upon binding the MDM2 hydrophobic 
pocket       
  
The tumour suppressor protein (p53) is a major cell cycle regulator that tightly binds the MDM2 
hydrophobic cleft. The pocket-like nature of the MDM2 p53-binding domain targets the N-terminal 
transactivation domain of p53 allowing three critical residues (PHE19, TRP23, and LEU26) to be 
deeply buried (Patil et al., 2014). In the present study, molecular docking studies show that ezetimibe 
binds the MDM2 hydrophobic pocket in a manner that accurately resemble p53 (Figure 4.18 and 4.19). 
This binding mode guarantees a complete inhibition of p53, and thus blocking the formation of MDM2-
p53 complexes. 
Current studies, show that nutlins (categorised within the piperazine class) are the major p53 inhibitors 
binding the MDM2 hydrophobic cleft. In this study, the screened database (Zdd) does not include 
nutlins, however there is a collection of piperazine compounds which did not exhibit any binding to 
the MDM2 p53-binding domain. Therefore, these findings do not negate those of previous studies, but 
rather reports another class of compounds (Organoheterocyclic) more likely to target the MDM2 
hydrophobic pocket and thus reactive intracellular levels of p53. Therefore, this finding suggests that 
ezetimibe might be a very good lead compound possessing have significant implications in cancer 
therapy.             
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 Model-A represents the best possible RBBP6 p53-binding domain with minimal deviation from 
native state. 
 The RBBP6 p53-binding domain constitutes a mixture of helices and loop structures, however its 
global topology still needs further refinements.  
 RBBP6 interact with p53 in a different site compared to the transactivation domain targeted by 
MDM2, thus confirming that it acts as a scaffold promoting p53 ubiquination and its subsequent 
degradation.   
 RBBP6 is draggable and might be a good therapeutic target in cancer.   
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Modelling improvement  
In future studies, the global topology of the p53-binding domain would be improved by incorporating 
a detailed statistical assessment on structure prediction. This should be done in a setting that would 
take most factors into account; such as molecular dynamics of neighbouring domains and the 
possibility of homo or hetero-dimerisation. Furthermore, the fundamental principle underlying 
conventional methods in protein modelling relies on “homology’’ and that brings major limitations 
when modelling proteins with no homologous protein template from PDB (Protein databank). This 
limitation has significantly delayed the drug discovery process as multiple critical protein structures 
remains unknown. 
Therefore, I-TASSER, 3D-Jigsaw and other softwares were developed to work based on fragment 
assembly approach rather than searching for a specific protein template. These techniques have shown 
great advancement and significantly improved drug discovery processes. However, for poor aligning 
proteins the modelling is still severely challenged. Hence the next adventure in modelling the RBBP6 
p53BD would be to use QUARK, which is a template-free modelling software that uses ab initio 
algorithms and Replica Exchange Monte Carlo Simulations. Finally, after these in sillico attempts 
HDX-MS and X-ray Crystallography would be used to predict the domain structure in an in vitro setup.   
Lead Optimisation                           
The optimisation of predicted lead compounds would also be performed using Glide XP (Extra 
Precision), Prime MM-GBSA and FEP+ Technology to generate preclinical drug candidates. For 
example; the optimisation of catechins with an aim of eliminating binding to anticancer drugs whilst 
maintaining their binding efficacy with RBBP6, might shed new light of their use in cancer therapy. 
However, ezetimibe has been shown to possess vulnerable sites on which glucuronidation takes place 
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(appendix 6). These sites would be of greater significance during optimisation to prevent metabolic 
fate and degradation of ezetimibe.     
Toxicity prediction and final testing 
This would then be followed up by in silico toxicity prediction of all the most promising lead 
compounds using Schrödinger-Maestro v10.7 and discovery studio. Druggable properties including 
pharmacokinetics would then be tested to all optimised compounds (pre-clinical drug candidates), and 
several in vitro assays (toxicity, specificity assays etc) would be done to validate these in silico 
predicted drug-like properties. Modern technologies such as Xcelligence and flow cytometry would be 
performed to assess the impact of the optimised drug candidates on cell-viability using various normal 
and cancer cell-lines (MCF-7, MRC-5, HEK293 etc). Finally, these drugs would be further tested in 
mince (in vivo studies) with varying concentrations. The data retrieved from all these tests would then 
be used as basis for designing new cancer therapies.     
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8.2 Appendices    
  
Ramachandran plots of the first three models generated by eThread–Modeller: Stereochemistry 
Assessment 
Appendix 1: Model-D plot showing sterically allowed and disallowed residues based on Psi and 
Phi angles  
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Appendix 2: Model-E plot showing sterically allowed and disallowed residues based on Psi and 
Phi angles 
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Appendix 3: Model-F plot showing sterically allowed and disallowed residues based on Psi and 
Phi angles   
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Appendix 4: eThread-Modeller: Main chain parameters of Model-D, E and F respectively 
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Appendix 5: PDB retrieved templates by eThread-Modeller during the p53BD domain modelling  
  Template   Identity   Confidence   Coverage   Length   
  4fmuA   0.315   T/0.00   0.330   37   
  1e5wA   0.286   T/0.23   1.000   112   
  5fm9A   0.243   T/0.78   1.000   112   
  2mbfA   0.192   L/0.49   0.562   63   
  4yycA   0.378   L/0.69   0.625   70   
  1lt7A   0.342   L/0.52   0.339   38   
  4kbgB   0.339   L/0.47   0.339   38   
  1vtnC   0.162   L/0.53   0.562   63   
  3soaA   0.423   L/0.57   0.161   18   
  2k7nA   0.234   L/0.59   0.116   13   
  4p4kC   0.270   L/0.48   0.330   37   
  4om8B   0.355   L/0.51   1.000   112   
  4onhB   0.315   L/0.47   1.000   112   
 
Identity: Is the global sequence identity to the target. 
Confidence: Estimates the chances that the template is structurally similar to the target (H - high, L - 
low, T - top). 
Coverage: Gives the coverage of the target sequence by the template. 
Length: Is the alignment length 
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Appendix 6: Biotransformation pathway of ezetimibe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 6: Biotransformation pathway of ezetimibe: [A] The metabolic pathway for ezetimibe in humans 
and pre-clinical species. [B] shows the major metabolite (Ezetimibe-glucuronide) formation together with the 
enzymes responsible for the reaction (Adapted from: Kosoglou et al., 2005).  
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